Status:
RECRUITING
A Real World Study About PMN
Lead Sponsor:
Wei Chen
Conditions:
Primary Membranous Nephropathy
Eligibility:
All Genders
18+ years
Brief Summary
The investigators designed a randomized, controlled, multicenter clinical study to compare the efficacy and safety of rituximab combined with hormones versus rituximab monotherapy in the treatment of ...
Detailed Description
Outcomes * Primary objective Treatment of primary membranous nephropathy with conventional clinical protocols and observation of its effectiveness and safety in a wide population. * Exploratory purpo...
Eligibility Criteria
Inclusion
- 1\. Diagnosed as primary membranous nephropathy (PMN) by renal biopsy; 2. Aged over 18 years; 3. An average 24-hour urine protein ≥ 3.5g twice a week after treatment with ACE inhibitors or ARBs for at least 3 months.
- \-
Exclusion
- With secondary membranous nephropathy (such as hepatitis B and C, systemic lupus erythematosus, drug therapy, malignant tumors and other secondary causes);
- Active infection, such as active hepatitis B or hepatitis C, tuberculosis (evidence of active tuberculosis infection within 1 year), or human immunodeficiency virus HIV infection (positive for anti-HIV antibodies), etc.
- A history of immunodeficiency, including other acquired or congenital immunodeficiency diseases, or organ transplantation.
- \-
Key Trial Info
Start Date :
November 11 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 11 2027
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06893328
Start Date
November 11 2024
End Date
November 11 2027
Last Update
August 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wei Chen
Guangzhou, Guangdong, China, 510080